News

Amylyx Pharmaceuticals, a company developing a innovative therapeutic for amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), recently announced that former Biogen CEO Walter Gilbert, Ph.D and Nobel Laureate, will join Amylyx’s board of directors. “Dr. Gilbert brings an enormous breadth of experience as a scientist, biotech founder,…

Researchers have identified an essential protein, Pur-alpha, for motor neuron cells’ mechanisms of defense against external stress and degeneration and also as a potential new therapeutic target for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease). The research paper, “Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates…

A recent review summarized the effects of immune system dysregulation and neuroinflammation in the regulation of critical pathways associated with depression and other brain disorders, including amyotrophic lateral sclerosis (ALS). The researchers specifically focused on extracellular vesicles (EVs) as potential biomarkers and drug delivery vehicles. The review, “Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles…

Cytokinetics Inc. has presented its Vision 2020: Empowering Our Future – an initiative designed to expand the company’s pipeline until 2020, as well as advance its muscle biology-directed drug candidates toward late-stage development and marketing strategies, to tackle the unmet medical needs of people living with impaired muscle…

The ratio of N-acetyl aspartate (NAA) to glutamate is related to disease duration in patients with amyotrophic lateral sclerosis (ALS), a finding that supports the notion of glutamate toxicity as a contributing factor in ALS pathology. Earlier studies have indicated that the neurotransmitter glutamate is involved in ALS. People with sporadic ALS…

A panel of leading amyotrophic lateral sclerosis (ALS) researchers recently published a review study, supported by the ALS Association, detailing the state of disease biomarker development and calling for the formation of an ALS Biomarker Consortium to speed up research into more effective disease treatments. The review, titled “ALS biomarkers…

Motor neuron degeneration in amyotrophic lateral sclerosis (ALS) patients is caused by several factors, including inflammation and oxidative stress. Uncovering the multiple pathways leading to ALS may suggest new ways to intervene therapeutically. University of Pittsburgh researchers found the Receptor for Advanced Glycation End Products (RAGE) and its ligands, or…

A report in the journal JAMA Neurology revealed positive findings from the first Phase 1/2 clinical trial and the Phase 2 dose escalation study investigating BrainStorm’s NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). NurOwn is a stem cell technology employing adult cells isolated from the disease-affected patient, developed…

Researchers at the National University of Singapore have suggested there is a fine balance between amyotrophic lateral sclerosis (ALS)-related protein TDP-43’s normal function and its potential to cause neurodegeneration. The degeneration seems to occur due to pathological factors that exaggerate the protein’s membrane association, resulting in the loss of its physiological functions as well as…

University of Bern researchers have discovered that the synaptic protein Homer-3 is linked to the death of Purkinje motor neurons in Spinocerebellar ataxia type 1 (SCA1), a motor neuron disease that, like amyotrophic lateral sclerosis (ALS), is characterized by extensive motor neuron loss. The study, titled “Impaired mTORC1-Dependent Expression of…